Global HPV Testing and PAP Test Market 2022: Continuous Clinical Trials, Developments, and Product Launches Propel Sector
Global HPV Testing and PAP Test Market
Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "HPV Testing and PAP Test Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global HPV testing and PAP test market reached a value of US$ 3.73 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 5.37 Billion by 2027, exhibiting a CAGR of 6.26% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test.
These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
HPV Testing and PAP Test Market Trends:
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth.
In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor.
This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
Key Market Segmentation
Breakup by Test Type:
HPV Test
Pap Test
Co-testing
Breakup by Product:
Instruments
Consumables
Services
Breakup by Application:
Cervical Cancer Screening
Vaginal Cancer Screening
Breakup by End User:
Hospitals and Clinics
Laboratories
Diagnostic Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
5 Global HPV Testing and PAP Test Market
6 Market Breakup by Test Type
7 Market Breakup by Product
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Analysis
15 Competitive Landscape
Companies Mentioned
Abbott Laboratories
Arbor Vita Corporation
AstraZeneca plc
Becton Dickinson
Company
Biocon Limited
bioMerieux SA
Danaher Corporation
F. Hoffmann-La Roche AG
Hologic Inc.
NURX Inc. (Thirty Madison Inc.)
Qiagen N.V.
Quest Diagnostics Incorporated
Seegene Inc.
Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/q488v9
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900